Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 594,403
  • Shares Outstanding, K 333,934
  • Annual Sales, $ 164,070 K
  • Annual Income, $ -372,180 K
  • EBIT $ -399 M
  • EBITDA $ -365 M
  • 60-Month Beta 1.06
  • Price/Sales 3.56
  • Price/Cash Flow N/A
  • Price/Book 0.76

Options Overview Details

View History
  • Implied Volatility 194.97% ( +72.10%)
  • Historical Volatility 189.22%
  • IV Percentile 81%
  • IV Rank 23.24%
  • IV High 715.60% on 04/10/25
  • IV Low 37.36% on 08/15/24
  • Put/Call Vol Ratio 0.07
  • Today's Volume 1,377
  • Volume Avg (30-Day) 5,207
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 169,803
  • Open Int (30-Day) 156,954

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.28
  • Number of Estimates 5
  • High Estimate -0.23
  • Low Estimate -0.34
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6385 +8.64%
on 05/19/25
3.7300 -52.28%
on 05/05/25
-1.4100 (-44.20%)
since 04/23/25
3-Month
1.6385 +8.64%
on 05/19/25
5.8750 -69.70%
on 02/24/25
-4.0000 (-69.20%)
since 02/21/25
52-Week
1.6385 +8.64%
on 05/19/25
12.5050 -85.77%
on 11/07/24
-8.4800 (-82.65%)
since 05/23/24

Most Recent Stories

More News
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting

IOVA : 1.7800 (+1.71%)
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

IOVA : 1.7800 (+1.71%)
ONC : 241.43 (+1.12%)
SMMT : 25.85 (+0.31%)
MRK : 77.58 (-0.33%)
VRTX : 436.00 (+0.45%)
PFE : 23.32 (+1.22%)
BMY : 46.85 (-0.38%)
Down More Than 75% This Year, Should Investors Throw in the Towel on Iovance Biotherapeutics Stock?

IOVA : 1.7800 (+1.71%)
This Natural Killer Treatment Could Help Transform How Cancer is Treated

GT Biopharma (NASDAQ: GTBP) just initiated the dosing in Cohort 2 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic...

PYXS : 1.2300 (+2.50%)
IOVA : 1.7800 (+1.71%)
BTAI : 1.3900 (+1.46%)
GTBP : 2.89 (+8.24%)
FATE : 1.1600 (-3.33%)
Why Iovance Biotherapeutics Tumbled by Nearly 6% Today

NFLX : 1,185.39 (-0.22%)
NVDA : 131.29 (-1.16%)
IOVA : 1.7800 (+1.71%)
UBS : 31.74 (-1.18%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

IOVA : 1.7800 (+1.71%)
Is This Beaten-Down Stock a Buy Near Its 52-Week Low?

IOVA : 1.7800 (+1.71%)
3 Monster Stocks in the Making

VKTX : 26.98 (-2.70%)
IOVA : 1.7800 (+1.71%)
AXSM : 105.07 (+0.69%)
Why Iovance Biotherapeutics Stock Is Crashing Today

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were crashing 46.6% lower as of 10:40 a.m. ET on Friday. The huge decline came after the drugmaker announced its first-quarter results before the market...

IOVA : 1.7800 (+1.71%)
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

Iovance Biotherapeutics, Inc. IOVA incurred a first-quarter 2025 loss of 36 cents per share, wider than the Zacks Consensus Estimate of a loss of 25 cents. In the year-ago quarter, the company reported...

BEAM : 16.83 (-2.38%)
IOVA : 1.7800 (+1.71%)
ELEV : 0.3157 (-1.65%)
ADPT : 8.93 (+1.02%)

Business Summary

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own...

See More

Key Turning Points

3rd Resistance Point 1.9433
2nd Resistance Point 1.8667
1st Resistance Point 1.8233
Last Price 1.7800
1st Support Level 1.7033
2nd Support Level 1.6267
3rd Support Level 1.5833

See More

52-Week High 12.5050
Fibonacci 61.8% 8.3540
Fibonacci 50% 7.0718
Fibonacci 38.2% 5.7895
Last Price 1.7800
52-Week Low 1.6385

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar